ReviewClinical ophthalmology (Auckland, N.Z.)2026
The Acute Effects of Caffeine on OCT and OCTA Parameters: A Systematic Review and Meta-Analysis.
Review in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This systematic review and meta-analysis aimed to comprehensively assess the acute effects of caffeine and caffeinated beverages on ocular microvasculature measured by optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) parameters, explicitly focusing on subfoveal choroidal thickness (SFCT) and superficial capillary vessel density (SVD), and deep capillary vessel density (DVD). Methods: A systematic search was conducted across PubMed, the Cochrane Database, and Embase for trials evaluating the acute effects of caffeine or caffeinated beverages on SFCT, SVD, and DVD, as measured by OCTA. Pooled mean differences (MD) were calculated using random-effects models, with heterogeneity assessed by I Results: 18 studies comprising 630 patients were included. Pooled analysis demonstrated a significant reduction in SFCT after caffeine intake (-23.79 μm; 95% CI: -31.43 to -16.15; p < 0.001), particularly with coffee and caffeine capsules, whereas no effect was observed with energy drinks or in highly myopic eyes. Regarding SVD, caffeine was associated with significant reductions across foveal, parafoveal, and perifoveal regions, mainly driven by coffee and capsule interventions. In DVD analyses, no overall significant effect was found; however, subgroup analyses indicated significant reductions with caffeine capsules and coffee, while energy drinks showed opposite trends. Conclusion: Acute caffeine intake, primarily from capsules or coffee, induces significant SFCT reduction and modest reductions in SVD, while changes in DVD were confined mainly to the caffeine-capsule subgroup, suggesting that energy drink ingredients may counteract caffeine-induced vasoconstriction. These findings offer valuable insights into the acute effects of caffeine on ocular microvasculature; however, the modest effect sizes necessitate caution regarding inherent physiological, measurement, and bioactive components variability. This study establishes a foundation for future investigations into the clinical significance of acute ocular microvascular fluctuations following caffeine intake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.